Market Place
Sourcing Support
Lantheus acquires Alzheimer’s PET diagnostic developer Meilleur Technologies
16 Jul 2024 //
FIERCE BIOTECH
Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies
01 Mar 2021 //
BUSINESSWIRE
PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent
09 Dec 2020 //
UROTODAY
Lantheus Holdings Announces Acceptance of NDA for PyLTM (18F-DCFPyL)
09 Dec 2020 //
BUSINESSWIRE
Lantheus Holdings Announces Presentations at the 33rd (EANM) Virtual Congress
08 Oct 2020 //
BUSINESSWIRE
Lantheus Holdings Submits New NDA to the U.S. FDA for PyL™ (18F-DCFPyL)
30 Sep 2020 //
BUSINESSWIRE
Lantheus files U.S. application for PET imaging agent for prostate cancer
30 Sep 2020 //
SEEKING ALPHA
Lantheus Holdings Submits NDA to the USFDA for PyL™ (18F-DCFPyL)
29 Sep 2020 //
BUSINESSWIRE
ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus
15 Apr 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.